Lilly Presents Results of Mirikizumab in P-II SERENITY Study for Crohn's Disease at DDW 2021
Shots:
- The P-II SERENITY study involves assessing mirikizumab (200/600/1000mg) vs PBO in patients in a ratio (2:1:1:2) with mod. to severely active CD for 12wks.
- Patients showed improvement in fatigue @12wks. as measured by the mean change in FACIT-Fatigue scores with improvements that sustained up to 1yr. At the end of the 12wks. period- patients treated with mirikizumab who achieved ≥1 point improvement in SES-CD were re-randomized in a ratio (1:1) to continue to receive the same- once-monthly mirikizumab (IV or SC- 300mg)- up to 52wks.
- Three analyses of the RWE data also highlight the burden of fatigue and rectal urgency among people living with UC and CD
Ref: PRNewswire | Image: Forbes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com